Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002202 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 141W94 and Indinavir in HIV-Infected Patients
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT00002202: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002202 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 460 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002202, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
Interventions
- DRUG Indinavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Phase | Phase 3 |
What the finished NCT00002202 record still lists
NCT00002202 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002202 about?
NCT00002202 is a clinical study titled "A Comparison of 141W94 and Indinavir in HIV-Infected Patients". The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
What is the current status of trial NCT00002202?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants.
What interventions are being tested in trial NCT00002202?
The interventions under investigation include: Indinavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002202?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002202's enrollment target sits among peer trials
460 823rd of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE